C
Chameleon Biosciences
Transforming gene therapy with a re-dosable, AAV based gene therapy
About Chameleon Biosciences
Chameleon Biosciences is a biotechnology company focused on developing gene therapies for rare genetic disorders. The company operates in the healthcare and biotechnology market, specifically targeting conditions such as Niemann-Pick Type C, Hemophilia, Duchenne Muscular Dystrophy, and other severe genetic diseases. Chameleon Biosciences serves patients and healthcare providers by offering innovative treatments designed to address significant unmet medical needs. The business model revolves around research and development of gene therapies, conducting clinical trials, and eventually commercializing these therapies. Revenue is generated through the sale of these therapies, partnerships with pharmaceutical companies, and potential licensing agreements. The company's mission is to provide life-changing, re-dosable gene therapies that offer longer, healthier lives for patients, including children and adults.
Source: Dealroom company dataNews
Open roles
Chameleon Biosciences in the Berkeley ecosystem
The Chameleon Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Berkeley SkyDeck VC
Matrix Partners China
Tachyon Valley BioLabs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chameleon Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chameleon Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

